Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Senna M, Taylor S, Piraccini B, Shapiro J, Somani N, Jedynak J, Ogwu S, Buchanan A, Craiglow B, Ohyama M. Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s522. DOI: 10.25251/skin.9.supp.522.Peer-Reviewed Original ResearchSeverity of Alopecia ToolLoss of responseSeverity of Alopecia Tool scoreBaricitinib 4 mgLost responseMaintenance treatmentAlopecia areataLong-term maintenance therapyYears of initial treatmentWeeks of maintenance treatmentBaseline disease characteristicsSevere alopecia areataPhase 3 trialYear of treatmentPost Hoc AnalysisBaricitinib monotherapySevere AAMaintenance therapySALT scoreMaintained responseInitial treatmentBaseline characteristicsAdjunctive therapyTreatment responseCOVID-19 infection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply